Integer Holdings Corp: 1 director

A director at Integer Holdings Corp sold 1,500 shares at 114.000USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Sogeclair: 1 director

A director at Sogeclair bought 3,710 shares at 21.400EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Onward: Model Update

We update our financial model after Onward medical released FY 2023 results last week The rating remains unchanged with a Buy recommendation and EUR 20 PT.

INVEST SECURITIES - WORLDLINE : Avis contrariant réaffirmé après un T1...

Mytilineos S.A.: 1 director

A director at Mytilineos S.A. sold 8,694 shares at 38.574EUR and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Q1 report: ReTRIACt slower than expected

Q1 first take: soft wind and higher costs

Aperam : Decent Q1 set of results, Q2 outlook on higher demand but mar...

>Soft results as expected with stainless weakness offset by recycling and alloys - Aperam delivered decent Q1 results with adjusted EBITDA at € 55m, stable on Q4 in line with the group guidance and above the consensus at € 52m and our own expectations of € 48m. Positively, the core Stainless & Electrical division returned to profits (€ 14m EBITDA), although that was mostly driven by lower inventory valuation losses. Volumes were otherwise decent notably in Europe (per...

Shurgard : T1 2024 – Performance opérationnelle globalement en ligne

>Guidance 2024 confirmée sur la base d’une dynamique opérationnelle globalement stable - La publication de Shurgard sur le T1 24 (i.e. revenus à 93.4 M€ ; croissance à périmètre courant et taux de change constants à +7.1%) traduit le maintien d’une performance opérationnelle globalement stable :Shurgard continue de bénéficier globalement d’une bonne tension locative avec un taux d’occupation « same stores » à 89.2% (soit une baisse de 60 pb yoy) proche de sa cibl...

Bonduelle : Q3 sales below expectations. Full-year organic growth guid...

>Organic sales decline of 1% vs +5%e with Europe stable and non-Europe down 3% - Bonduelle's Q3 sales, reported yesterday evening, fell 4% short of our forecast with a less negative forex effect than expected. Sales of € 564.9m (vs € 588.1m) came in 1.3% lower in reported terms and -1% in organic terms (vs +5%). Sales for the two zones were lower in organic terms. Europe sales posted a slight increase of 0.5% in reported terms and were flat on an organic basis at € 37...

LNA Santé : Q1 2024 revenue: solid - 2024 healthcare tariffs not parti...

>Q1 revenue: robust organic growth - LNA Santé has reported Q1 revenue of € 189.3m, up 6.9% (+6.9% l-f-l). Occupancy rates at cruising speed, excl. hospital care at home, stood at 99%, up 1.6 points vs Q1 2023. LNA reiterated its target for organic growth of 4.5%, i.e. operating income of >€ 750m (i.e. >+4.2%) for an EBITDA margin excl. IFRS of 11% (vs 10.8% in 2023). That said, LNA noted the latest elements relating to 1/ the 2024 tariff campaign for post-acute/...

Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)

This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...

Stockholm continue to stand out

PLDT Inc.: Update to credit analysis

Our credit view of PLDT Inc. reflects its defendable and leading revenue market position in the Philippines' telecommunications sector, offset by marginally higher leverage.

Galapagos : Une publication sans grande surprise

>Une trésorerie solide - Galapagos publiait après la fermeture du marché US ses résultats du T1. Les revenus du groupe ressortent ainsi à 100 M€ vs 83 M€ att. L’essentiel des revenus vient de son accord avec Gilead pour 62 M€ alors que les ventes des produits nets ressortent à 37 M€. Au niveau opérationnel, les coûts sont globalement bien maitrisés ce qui conduit à avoir des dépenses totales de l’ordre de 129 M€ vs 110 M€ même si nous observons une hausse de près...

RATIONAL AG : Positive margin performance in 2024

>Conference call feedback: sales and profitability - During the conference call, management discussed the group’s developments in Q1 as well as the growth forecast for the full year. The key takeaways were :For Q1, sales were up 1% at € 293m despite a demanding comparison base (Q1 2023: +25%). By region, we note dynamic momentum in the Americas and Asia (+11% and +18% respectively) benefiting from the upturn in demand on underpenetrated markets, as well as signif...